Biohaven Slides 5.5% as Market Confidence Wavers on 2024 11‑26
Biohaven shares tumble 5.5% as market doubts grow over its clinical‑stage promise, prompting investors to question the sustainability of its high valuation.
3 minutes to read
BIOHAVEN LTD
Biohaven’s FDA Acceptance of Vyglxia Resubmission Signals 2027 Review & Upside
Biohaven’s FDA‑accepted Vyglxia resubmission sparks a potential 2027 review, boosting investor optimism and setting the stage for a regulatory‑stage breakthrough.
4 minutes to read